Sayana® Press (SP) is a 104-mg single dose of medroxyprogesterone acetate (MPA) in 0.65-mL volume, sterilely packaged in the Uniject device. Uniject is a pre-filled, non-reusable blister injection system consisting of a bubble reservoir with an integral, ultra-thin needle. (For a picture of SP, see below and Fig 1 in both accompanying papers by Keith [
- Keith B.
- Wood S.
- Tifft S.
- Hutchings J.
Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings.
Contraception. 2014; 89: 344-351
2].) In this issue of Contraception, a group of papers address the acceptability of Sayana® Press (also known as Depo subQ Provera 104™ in Uniject) and other research related to this new product. These papers also identify some of the challenges to SP reaching its full potential as a new contraceptive option in low-resource settings, especially in sub-Saharan Africa and South and Central Asia, where unmet need for family planning is the greatest. SP could be a “game changer,” in part, due to its potential for in-home or self-injection. In addition, given the safety and ease of subcutaneous injections with SP, some Ministries of Health may be more likely to enact policy change to permit community health workers (CHWs) and other community-level workers (e.g., drug shop keepers) to provide injectables in countries that currently only permit higher level providers to do so. At a reasonable price, this new product has the potential to expand contraceptive choice and use in underserved communities that otherwise might not have access to injectable contraceptives.
- Keith B.
- Wood S.
- Chapman C.
- Alemu E.
Perceptions of home and selfinjection of Sayana® Press in Ethiopia: a qualitative study.
Contraception. 2014; 89: 379-384
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings.Contraception. 2014; 89: 344-351
- Perceptions of home and selfinjection of Sayana® Press in Ethiopia: a qualitative study.Contraception. 2014; 89: 379-384
- Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.Contraception. 2014; 89: 352-356
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.Contraception. 2014; 89: 31-35
Arias R. Personal Communication. Presentation given by Dr. Arias during the Pfizer seminar on this new product at FIGO2003, Santiago, Chile.
- Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.Contraception. 2014; 89: 361-367
- Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.Contraception. 2014; 89: 368-373
- Members of the Rakai Health Sciences Program Sayana Press Study Team. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.Contraception. 2014; 89: 385-395
- Operational assessments of Sayana® Press provision in Senegal and Uganda.Contraception. 2014; 89: 374-378
Published online: March 03, 2014
Accepted: February 19, 2014
Received: February 19, 2014
☆Disclaimer: “The views of author do not necessarily represent those of the United States Agency for International Development.”
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.